Duration of Valganciclovir Maintenance Therapy for CMV Retinitis
Valganciclovir maintenance therapy should be continued for life unless immune reconstitution occurs with CD4+ counts sustained above 100 cells/µL for 3-6 months on antiretroviral therapy. 1
Lifelong Maintenance: The Default Approach
After completing induction therapy for CMV retinitis, chronic maintenance therapy (secondary prophylaxis) is recommended indefinitely unless specific criteria for discontinuation are met 1. This recommendation carries the highest level of evidence (AI rating) and reflects the natural history of CMV retinitis in immunocompromised patients—before the antiretroviral therapy (ART) era, retinitis typically reactivated within 6-8 weeks after stopping treatment 1.
Effective maintenance regimens include:
- Oral valganciclovir (preferred for convenience)
- Parenteral ganciclovir
- Parenteral foscarnet
- Parenteral cidofovir
- Ganciclovir intraocular implant (for retinitis only, should be combined with oral valganciclovir) 1
When to Discontinue: The Immune Reconstitution Exception
Discontinuation criteria (all must be met):
- CD4+ count sustained >100 cells/µL for 3-6 months in response to ART
- Decision made in consultation with an ophthalmologist
- Consider: anatomic location of retinal lesions, vision in contralateral eye, feasibility of regular ophthalmologic monitoring 1
The evidence supporting safe discontinuation comes from multiple case series showing patients remained disease-free for 30-95 weeks after stopping therapy when immune recovery occurred 1. The CD4+ count—not HIV viral load—is the primary determinant of immune recovery to CMV 1.
Critical Post-Discontinuation Monitoring
Even after stopping maintenance therapy, patients require:
- Regular ophthalmologic examinations every 3 months (minimum) to detect early relapse or immune recovery uveitis 1
- Awareness that relapse risk is 3% per year, and relapses have occurred even at CD4+ counts of 1,250 cells/µL 1
- CMV viral load monitoring is NOT recommended as it has poor positive predictive value for retinitis relapse 1
When to Restart Maintenance Therapy
Reinstitute secondary prophylaxis when:
- CD4+ count decreases to <100 cells/µL (especially if <50 cells/µL, where relapse occurs frequently) 1
- Any clinical evidence of CMV retinitis reactivation 1
Important Caveats
Vision-threatening lesions: Patients with retinitis immediately threatening sight may benefit most from ganciclovir intraocular implant combined with oral valganciclovir due to superior local drug concentrations and ability to control progression 1. However, implant replacement at 6-8 months may not be necessary if sustained immune recovery occurs 1.
Non-retinitis CMV disease: Chronic maintenance is NOT routinely recommended for gastrointestinal CMV disease (consider only if relapses occur), and no established role exists for CMV pneumonitis maintenance 1.
Special populations: The decision to continue or discontinue must account for the patient's ability to adhere to regular ophthalmologic follow-up, as missed monitoring could result in irreversible vision loss before relapse is detected 1.
The algorithmic approach is straightforward: continue maintenance indefinitely unless immune reconstitution with sustained CD4+ >100 cells/µL for 3-6 months allows safe discontinuation under close ophthalmologic surveillance, with readiness to restart if CD4+ drops below 100 cells/µL.